Patient Immune Response to Tumors Monitored Using Scid Mouse Models

References

• Czerkinsky C, Anderson G, Ekre H-P, Nilsson L, Klareskog L-A, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 1998; 110: 29–36
   Google Scholar
• Herr W, Schneider J, Ansgar L W, Meyer zum Buschenfelde K-H, Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods 1996; 191: 131–142
   PubMedGoogle Scholar
• Scheibenbogen C, Lee K-H, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee H-G, Keilholz U. Analysis of the T-cell response to tumor and viral peptide antigens by an IFN-y-ELISPOT assay. Intl. J. Cancer 1997; 71: 1–5
   PubMedGoogle Scholar
• Scheibenbogen C, Lee K-H, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee H-G, Keilholz U. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 1997; 3: 221–226
   PubMedGoogle Scholar
• Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde K-H, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J. Immunol. Meth. 1997; 203: 141–151
   PubMed Web of Science ®Google Scholar
• Altman J D, Moss P, Goulder P. Phenotypic analysis-specific T lymphocytes. Science 1996; 274: 94–96
   PubMed Web of Science ®Google Scholar
• Dal Porto J, Johansen T E, Catipovic B. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc. Natl. Acad. Sci. USA 1993; 90: 6671–6675
   PubMed Web of Science ®Google Scholar
• Greten T F, Slansky J E, Kubota R. Direct visualization of antigen-specific T cells: HTLV-1 Tax 11–19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. USA 1998; 95: 7568–7753
   PubMed Web of Science ®Google Scholar
• Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 1981; 126: 614–619
   PubMedGoogle Scholar
• Pass H A, Schwarz S L, Wunderlich J R, Rosenberg S A. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using ELISPOT assay. Cancer J. Sci. Amer. 1998; 4: 316–323
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Yang J C, Schwartzentruber D J, Hwu P, Marincola F M, Topalian S M, Restifo N P, Dudley ME, Schwarz S L, Spiess P J, Wonderlich JR, Parkhurst M R, Kawakami Y, Seipp C A, Einhorn J H, White D E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998; 4: 321–327
   PubMed Web of Science ®Google Scholar
• Asai T, Storkus W J, Whiteside T L. Evaluation of the modified ELISPOT assay for interferon-y production in monitoring of cancer patients receiving anti-tumor vaccines. Clin. Diagn. Lab. Immunol. 1999, in press
   Google Scholar
• McMichael A J, O'Callaghan C A. A new look at T cells. J. Exp. Med. 1998; 187: 1367–1371
   PubMed Web of Science ®Google Scholar
• Howard M C, Spack E G, Choudhury K, Greten T F, Schneck J P. MHC-based diagnostics and therapeutics—clinical applications for disease-linked genes. Immunol. Today 1999; 20: 161–165
   PubMedGoogle Scholar
• Romero P, Dunbar P R, Valmori D, Pittet M, Ogg G S, Rimoldi D, Chen J L, Lienard D, Cerottini J C, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J. Exp. Med. 1998; 188: 1641–1650
   PubMed Web of Science ®Google Scholar
• Pittet M J, Valmori D, Dunbar P R, Speiser D E, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini J C, Romero P. High frequencies of naive melan-A/MART-1 -specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 1999; 190: 705–715
   PubMed Web of Science ®Google Scholar
• Reddy S, Piccione D, Takita H, Bankert R B. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 1987; 47: 2456–2460
   PubMed Web of Science ®Google Scholar
• Mosier D E, Gulizia R J, Baird S M, Wilson D B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (Lond.) 1988; 335: 256–259
   PubMed Web of Science ®Google Scholar
• Williams S S, Chen F-A, Kida H, Yokota S, Miya K, Kato M, Barcos M P, Wang H-Q, Alosco T, Umemoto T, Croy B A, Repasky E A, Bankert R B. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol. 1996; 156: 1908–1915
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J. Exp. 1993; 178: 1103–1107
   PubMed Web of Science ®Google Scholar
• Williams S S, Umemoto T, Kida H, Repasky E A, Bankert R B. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies. J. Immunol. 1992; 149: 2830–2836
   PubMed Web of Science ®Google Scholar
• Chen F-A, Williams S S, Fanslow W C, Bankert R B. Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand. J. Immunol. 1995; 155: 2833–2840
   PubMedGoogle Scholar
• Iwanuma Y, Chen F-A, Egilmez N K, Takita H, Bankert R B. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 1997; 57: 2937–2942
   PubMedGoogle Scholar
• Kuriakose M A, Chen F-A, Egilmez N K, Jong Y S, Mathiowitz E, DeLacure M D, Hicks W L, Jr., Loree T L, Bankert R B. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head and Neck 1999, in press
   Google Scholar
• Egilmez N K, Jong Y S, Hess S D, Jacob J S, Mathiowitz E, Bankert R B. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID/WINN model. J. Immunotherapy 1999, in press
   Google Scholar
• Dolman C S, Mueller B M, Lode N H, Xiang R, Gillies S D, Reisfeld R A. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin. Cancer Res. 1998; 4: 2551–2557
   PubMed Web of Science ®Google Scholar
• Burd R, Dziedzic T S, Xu Y, Caligiuri M A, Subjeck J R, Repasky E A. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J. Cell. Physiol. 1998; 177: 137–147
   PubMed Web of Science ®Google Scholar
• McCarty T M, Liu X, Sun J Y, Peralta E A, Diamond D J, Ellenhorn J D. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res. 1998; 58: 2601–2605
   PubMed Web of Science ®Google Scholar
• Walker W, Gallagher G. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice. Clin. Exp. Immunol. 1995; 101: 494–501
   PubMedGoogle Scholar
• Hirano A, Longo D L, Taub D D, Ferris D K, Young L.S., Eliopoulos A G, Agahanggelau A, Cullen N, McCartney J, Fanslow W C, Murphy W J. Inhibition of human breast carcinoma growth by a soluble ecombinant human CD40 ligand. Blood 1999; 93: 2999–3007
   PubMed Web of Science ®Google Scholar
• Schumacher U, Mitchell B S. Use of clinically relevant human-scid-mouse models in metastasis research. TIBTECH 1997; 15: 239–241
   PubMedGoogle Scholar